Onward Medical
reported EUR 2 million in first-quarter 2026 revenue, achieved first-in-human use of its ARC-IM lumbar lead designed to restore standing, stepping and lower-limb mobility after spinal cord injury, and enrolled its first patient in the Empower BP global pivotal study addressing post-injury blood pressure instability;…
- Country
- Netherlands
FDA cleared (ARC-EX)
Spinal cord injury
eu
Coverage
| CN | EU | US | |
|---|---|---|---|
| regenerative-personalized | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Bioelectronic medicine & neuromodulation | regenerative-personalized | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.